New drug cuts seizures by up to 91% in children with rare epilepsy

New drug cuts seizures by up to 91% in children with rare epilepsy

A new experimental drug is showing remarkable promise for children with Dravet syndrome, a severe genetic form of epilepsy. In clinical trials, the treatment zorevunersen cut seizures by as much as 91% while also improving quality of life for many patients. The therapy works by boosting the function of a key gene involved in nerve cell signaling. Encouraging results have led researchers to launch a larger Phase 3 trial.

A groundbreaking gene-based therapy cut seizures by up to 91% in children with Dravet syndrome, offering new hope for families facing this devastating epilepsy. An experimental therapy for children with a severe and difficult to treat form of epilepsy appears to be both safe and highly effective at reducing seizures, according to results from an international clinical trial led by UCL (University College London) and Great Ormond Street Hospital. The findings suggest the treatment could significantly improve the health and daily lives of affected children.


The study, published in The New England Journal of Medicine, found that children with Dravet syndrome experienced seizure reductions of up to 91 percent while regularly receiving an investigational drug called zorevunersen.

International Research Awards

Nomination link: https://researchawards.net/award-nomination-ecategoryawardsrcategoryawardee/?ecategory=Awards&rcategory=Awardee

Visit Our Website: researchawards.net
Contact Us: info@researchawards.net